Author:
Heidenreich Axel,Bach Christian,Pfister David
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Aus G, Hugosson J, Norlén L (1995) Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol 154(2 Pt 1):466–469
2. Piper C, Porres D, Pfister D, Heidenreich A (2014) The role of palliative surgery in castration-resistant prostate cancer. Curr Opin Support Palliat Care 8(3):250–257
3. Patrikidou A, Brureau L, Casenave J et al (2015) Locoregional symptoms in patients with de novo metastatic prostate cancer: morbidity, management, and disease outcome. Urol Oncol 33: 202:e9–17
4. Tan YG, Pang L, Khalid F, Poon R, Huang HH, Chen K, Tay KJ, Lau W, Cheng C, Ho H, Yuen J (2020) Local and systemic morbidities of de novo metastatic prostate cancer in Singapore: insight from 685 consecutive patients from a large prospective Uro-oncology registry. BMJ Open 10(2):e34331
5. Krupski TL, Stukenborg GJ, Moon K, Theodorescu D (2010) The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer. BJU Int 106:1477–1483